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Summary {#efs25465-sec-0001}
=======

Napropamide‐M is a new active substance for which, in accordance with Article 7 of Regulation (EC) No 1107/2009 of the European Parliament and of the Council (hereinafter referred to as 'the Regulation'), the rapporteur Member State (RMS), the United Kingdom, received an application from UPL Europe Ltd on 1 July 2015 for approval. Complying with Article 9 of the Regulation, the completeness of the dossier was checked by the RMS and the date of admissibility of the application was recognised as being 3 December 2015.

The RMS provided its initial evaluation of the dossier on napropamide‐M in the draft assessment report (DAR), which was received by the European Food Safety Authority (EFSA) on 2 June 2017. The peer review was initiated on 14 August 2017 by dispatching the DAR for consultation to the Member States and the applicant, UPL Europe Ltd.

Following consideration of the comments received on the DAR, it was concluded that additional information should be requested from the applicant, and that EFSA should conduct an expert consultation in the areas of mammalian toxicology, residues, environmental fate and behaviour and ecotoxicology.

In accordance with Article 12 of the Regulation, EFSA should adopt a conclusion on whether napropamide‐M can be expected to meet the approval criteria provided for in Article 4 of the Regulation taking into consideration recital (10) of the Regulation. Furthermore, this conclusion also addresses the assessment required from EFSA under Article 12 of Regulation (EC) No 396/2005, provided the active substance will be approved under Regulation (EC) No 1107/2009 without restrictions affecting the residue assessment.

The conclusions laid down in this report were reached on the basis of the evaluation of the representative uses of napropamide‐M as a herbicide on winter oilseed rape and brassica vegetable crops, as proposed by the applicant. Full details of the representative uses can be found in Appendix [A](#efs25465-sec-1002){ref-type="sec"} of this report.

The use of napropamide‐M according to the representative uses proposed at the European Union (EU) level results in a sufficient herbicidal efficacy against the target weeds.

A data gap was identified as regards the search of the scientific peer‐reviewed open literature on the active substance and its relevant metabolites in the area of ecotoxicology.

In the area of identity, physical chemical properties and analytical methods, data gaps were identified for data on oxidising properties of the active substance according to the UN test method for classification (CLP 1272/2008), for enantioselective monitoring methods for water and air, and for an analytical method for monitoring of all components of the residue definition in body fluids and tissues.

Regarding the mammalian toxicology area, several data gaps were identified. Validation of the analytical methods used in the developmental toxicity study in rat, which is a key study used for the derivation of the acute reference dose (ARfD) and acute acceptable operator exposure level (AAOEL), is missing. A data gap was identified for the assessment of the toxicological relevance of the individual impurities present in the technical specification in comparison with the toxicological profile of napropamide‐M, leading to a critical area of concern, because it is unknown whether the batches used in the toxicological studies for the derivation of the acceptable daily intake (ADI), ARfD and AAOEL support the technical specification. Other identified data gaps included an *in vitro* interspecies comparative metabolism study, phototoxicity and photomutagenicity testing (although no validated test guidelines are currently available), and historical control data to confirm that the increase in carcinogenic incidences observed at the top dose in the 2‐year rat study is not treatment‐related. The endocrine‐disrupting (ED) potential of napropamide‐M should also be clarified considering the effects observed in the apical studies on endocrine organs. Three of these data gaps led to issues that could not be finalised (the need for further tests and risk assessment to unique human metabolites, validation of the developmental toxicity study in rats, and the ED potential of napropamide‐M).

In the residue section, a number of data gaps were identified, i.e. on storage stability data in leafy crops, sufficient residue trials covered by storage stability and validated analytical method to support the representative use in leafy brassicas, field trials on rotational crops covering the maximum predicted environmental concentration in soil (PEC~soil~), and the magnitude of residues in pollen and bee products for human consumption covering also the succeeding crops. The consumer exposure is expected to be insignificant via food as the chronic and acute dietary intakes are less than 0.01% of the ADI and ARfD.

The data available on environmental fate and behaviour are sufficient to carry out the required environmental exposure assessments at EU level for the representative uses, with the notable exception that a reliable aerobic route of degradation of napropamide‐M in soil was not available. Consequently, the risk assessment to soil and aquatic organisms and the groundwater exposure for any transformation products that might be formed from napropamide‐M in soil is not finalised. Information is also missing regarding the effect of the water treatment process of ozonation and chlorination on the nature of the residues that might be present in surface water, when surface water is abstracted for drinking water. Consequently, the consumer risk assessment from the consumption of drinking water could not be finalised. The potential for groundwater exposure by napropamide‐M above the parametric drinking water limit of 0.1 μg/L was assessed as low for the representative uses.

In the area of ecotoxicology, several data gaps have been identified as regards aquatic organisms, bees and non‐target arthropods. Moreover, pending on the data gap identified in Section [4](#efs25465-sec-0009){ref-type="sec"} on the route of degradation in soil of napropamide‐M, further ecotoxicological assessments of metabolites might be necessary to address the potential risk to birds and mammals (when exposed to soil metabolites if translocated into the plant and via secondary poisoning), aquatic organisms, honeybees and soil organisms.

Background {#efs25465-sec-0003}
==========

Regulation (EC) No 1107/2009 of the European Parliament and of the Council[1](#efs25465-note-1004){ref-type="fn"} (hereinafter referred to as 'the Regulation') lays down, *inter alia*, the detailed rules as regards the procedure and conditions for approval of active substances. This regulates for the European Food Safety Authority (EFSA) the procedure for organising the consultation of Member States and the applicant(s) for comments on the initial evaluation in the draft assessment report (DAR), provided by the rapporteur Member State (RMS), and the organisation of an expert consultation, where appropriate.

In accordance with Article 12 of the Regulation, EFSA is required to adopt a conclusion on whether an active substance can be expected to meet the approval criteria provided for in Article 4 of the Regulation (also taking into consideration recital (10) of the Regulation) within 120 days from the end of the period provided for the submission of written comments, subject to an extension of 30 days where an expert consultation is necessary, and a further extension of up to 150 days where additional information is required to be submitted by the applicant(s) in accordance with Article 12(3).

Napropamide‐M is a new active substance for which, in accordance with Article 7 of the Regulation, the RMS, the United Kingdom (hereinafter referred to as the 'RMS'), received an application from UPL Europe Ltd on 1 July 2015 for approval. Complying with Article 9 of the Regulation, the completeness of the dossier was checked by the RMS and the date of admissibility of the application was recognised as being 3 December 2015.

The RMS provided its initial evaluation of the dossier on napropamide‐M in the DAR, which was received by EFSA on 2 June 2017 (United Kingdom, [2017](#efs25465-bib-0029){ref-type="ref"}). The peer review was initiated on 14 August 2017 by dispatching the DAR to the Member States and the applicant, UPL Europe Ltd, for consultation and comments. EFSA also provided comments. In addition, EFSA conducted a public consultation on the DAR. The comments received were collated by EFSA and forwarded to the RMS for compilation and evaluation in the format of a reporting table. The applicant was invited to respond to the comments in column 3 of the reporting table. The comments and the applicant\'s response were evaluated by the RMS in column 3.

The need for expert consultation and the necessity for additional information to be submitted by the applicant in accordance with Article 12(3) of the Regulation were considered in a telephone conference between EFSA and the RMS on 4 December 2017. On the basis of the comments received, the applicant\'s response to the comments and the RMS\'s evaluation thereof, it was concluded that additional information should be requested from the applicant, and that EFSA should conduct an expert consultation in the areas of mammalian toxicology, residues, environmental fate and behaviour and ecotoxicology.

The outcome of the telephone conference, together with EFSA\'s further consideration of the comments is reflected in the conclusions set out in column 4 of the reporting table. All points that were identified as unresolved at the end of the comment evaluation phase and which required further consideration, including those issues to be considered in an expert consultation, were compiled by EFSA in the format of an evaluation table.

The conclusions arising from the consideration by EFSA, and as appropriate by the RMS, of the points identified in the evaluation table, together with the outcome of the expert consultation where this took place, were reported in the final column of the evaluation table.

In accordance with Article 12 of the Regulation, EFSA should adopt a conclusion on whether napropamide‐M can be expected to meet the approval criteria provided for in Article 4 of the Regulation, taking into consideration recital (10) of the Regulation. A final consultation on the conclusions arising from the peer review of the risk assessment took place with Member States via a written procedure in September 2018.

This conclusion report summarises the outcome of the peer review of the risk assessment on the active substance and the representative formulation evaluated on the basis of the representative uses of napropamide‐M as a herbicide on winter oilseed rape and brassica vegetable crops, as proposed by the applicant. Furthermore, this conclusion also addresses the assessment required from EFSA under Article 12 of Regulation (EC) No 396/2005, provided the active substance will be approved under Regulation (EC) No 1107/2009 without restrictions affecting the residue assessment. In the event of a non‐approval of the active substance or an approval with restrictions that have an impact on the residue assessment, the maximum residue level (MRL) proposals from this conclusion might no longer be relevant and a new assessment under Article 12 of Regulation (EC) No 396/2005 will be required. A list of the relevant end points for the active substance and the formulation is provided in Appendix [A](#efs25465-sec-1002){ref-type="sec"}.

In addition, a key supporting document to this conclusion is the peer review report (EFSA, [2018](#efs25465-bib-0007){ref-type="ref"}), which is a compilation of the documentation developed to evaluate and address all issues raised in the peer review, from the initial commenting phase to the conclusion. The peer review report comprises the following documents, in which all views expressed during the course of the peer review, including minority views where applicable, can be found: the comments received on the DAR;the reporting table (13 December 2017);the evaluation table (10 October 2018);the reports of the scientific consultation with Member State experts (where relevant);the comments received on the assessment of the additional information (where relevant);the comments received on the draft EFSA conclusion.

Given the importance of the DAR including its revisions (United Kingdom, [2018](#efs25465-bib-0030){ref-type="ref"}) and the peer review report, both documents are considered as background documents to this conclusion.

It is recommended that this conclusion report and its background documents would not be accepted to support any registration outside the European Union (EU) for which the applicant has not demonstrated that it has regulatory access to the information on which this conclusion report is based.

The active substance and the formulated product {#efs25465-sec-0004}
===============================================

Napropamide‐M is the provisional approved ISO common name for (*R*)‐*N,N*‐diethyl‐2‐(1‐naphthyloxy)propionamide (IUPAC).

The representative formulated product for the evaluation was 'D‐Devrinol', a suspension concentrate (SC) containing 450 g/L napropamide‐M.

The representative uses evaluated were by broadcast soil spray application with or without incorporation against annual grasses and broad‐leaved weeds in winter oilseed rape and brassica vegetable crops. Full details of the Good Agricultural Practices (GAPs) can be found in the list of end points in Appendix [A](#efs25465-sec-1002){ref-type="sec"}.

Data were submitted to conclude that the uses of napropamide‐M according to the representative uses proposed at EU level result in a sufficient herbicidal efficacy against the target weeds, following the guidance document SANCO/10054/2013‐rev. 3 (European Commission, [2013](#efs25465-bib-0019){ref-type="ref"}).

A data gap has been identified for a more detailed assessment of the literature review in the area of ecotoxicology[2](#efs25465-note-1005){ref-type="fn"} (including search terms and applied relevance criteria) in accordance with the EFSA guidance on the submission of scientific peer‐reviewed open literature for the approval of pesticide active substances under Regulation (EC) No 1107/2009 (EFSA, [2011](#efs25465-bib-0005){ref-type="ref"}).

Conclusions of the evaluation {#efs25465-sec-0005}
=============================

1. Identity, physical/chemical/technical properties and methods of analysis {#efs25465-sec-0006}
===========================================================================

The following guidance documents were followed in the production of this conclusion: SANCO/3029/99‐rev. 4 (European Commission, [2000a](#efs25465-bib-0010){ref-type="ref"}), SANCO/3030/99‐rev. 4 (European Commission, [2000b](#efs25465-bib-0011){ref-type="ref"}) and SANCO/825/00‐rev. 8.1 (European Commission, [2010a](#efs25465-bib-0015){ref-type="ref"}).

The proposed specification for napropamide‐M is based on batch data from industrial plant production. The proposed minimum purity of the technical material is 930 g/kg. It should be noted that the evaluation of the toxicological relevance of the impurities is not concluded (see Section [2](#efs25465-sec-0007){ref-type="sec"}). There is no FAO specification available for napropamide‐M. The batches used in the toxicological assessment for the derivation of the acceptable daily intake (ADI), acute reference dose (ARfD) and acute acceptable operator exposure level (AAOEL) do not support the proposed specification (see Section [2](#efs25465-sec-0007){ref-type="sec"}).

The assessment of the data package revealed no issues that need to be included as critical areas of concern with respect to the identity, physical, chemical and technical properties of napropamide‐M or the representative formulation. However, a data gap for data on oxidising properties of the active substance according to the UN test method for classification (CLP 1272/2008) was identified. The main data regarding the identity of napropamide‐M and its physical and chemical properties are given in Appendix [A](#efs25465-sec-1002){ref-type="sec"}.

Adequate methods are available for the generation of pre‐approval data required for the risk assessment, except for the developmental toxicology study in rat (see Section [2](#efs25465-sec-0007){ref-type="sec"}). Methods of analysis are available for the determination of the active substance in the technical material and in the representative formulation and for the determination of the respective impurities in the technical material. It should be noted that evaluation of the toxicological relevance of the impurities is open and as a consequence, new data such as spectral data, content of the impurities before and after the storage of the formulation and methods for analysis of the relevant impurities in the formulation might be required.

Napropamide residues (sum of *R*‐ and *S*‐ isomers at any ratio) can be monitored in food and feed of plant origin by the Quick Easy Cheap Effective Rugged and Safe (QuEChERS) method using liquid chromatography with tandem mass spectrometry (LC--MS/MS) with a limit of quantification (LOQ) of 0.01 mg/kg in each commodity group.

An analytical method for food of animal origin is not required due to the fact that no residue definition is required.

Napropamide‐M and napropamide residues in soil can be determined by LC--MS/MS (using a chiral or non chiral column) with a LOQ of 0.01 mg/kg for each analyte.

Napropamide residues in drinking and surface water can be monitored by LC--MS/MS with a LOQ of 0.05 and 0.1 μg/L, respectively. It should be noted that the validated method is not enantioselective although a procedure for the determination of the enantiomeric ratio using a chiral column was included. A liquid chromatography‐ultraviolet detection (LC‐UV) method could be used for monitoring of napropamide residues in air with a LOQ of 3.33 × 10^−3^ mg/m^3^. The method is not enantioselective. The residue definitions in water and air include napropamide‐M, therefore data gaps for validation of enantioselective monitoring methods for water and air were identified.

In addition, it should be noted that the residue definition for monitoring in the environmental compartments is not finalised (see Sections [4](#efs25465-sec-0009){ref-type="sec"} and [5](#efs25465-sec-0010){ref-type="sec"}), therefore additional monitoring methods might be required.

The LC--MS/MS method can be used for monitoring of napropamide residues in body tissues with a LOQ of 0.01 mg/kg. Napropamide residues in body fluids can be determined by LC--MS/MS with a LOQ of 0.05 mg/L. None of the methods are enantioselective, but a procedure for the determination of the enantiomeric ratio using a chiral column was provided. However, the residue definition for body fluids and tissues was concluded as napropamide‐M, 4‐OGlu‐NOPAM, 4‐OGlu‐NOPA and 4‐Glu‐NPAM; as a consequence, a data gap for analytical methods for monitoring of all components of the residue definition was identified.

2. Mammalian toxicity {#efs25465-sec-0007}
=====================

The following guidance documents were followed in the production of this conclusion: SANCO/221/2000‐rev. 10‐final (European Commission, [2003](#efs25465-bib-0014){ref-type="ref"}), SANCO/10597/2003‐rev. 10.1 (European Commission, [2012](#efs25465-bib-0018){ref-type="ref"}), Guidance on dermal absorption (EFSA PPR Panel, [2012](#efs25465-bib-0008){ref-type="ref"}) and Guidance on the Application of the CLP Criteria (ECHA, [2017](#efs25465-bib-0001){ref-type="ref"}).

Napropamide‐M was discussed at the Pesticides Peer Review Experts' Teleconference 181 in June 2018.

The impurity profile of the batches of napropamide (racemate) used in the key studies to derive most of the toxicological reference values (i.e. ADI, ARfD and AAOEL) is unknown, and therefore, a data gap has been identified to assess the toxicological relevance of the individual impurities present in the technical specification, leading to a critical area of concern. Although acknowledging the lack of information on impurities, the RMS disagreed with this conclusion. It is however noted that the technical specification is supported by the toxicological assessment based on the batches used to test napropamide‐M (key study to establish the acceptable operator exposure level (AOEL) and to assess the genotoxic potential of the active substance). The analytical methods used in the toxicological studies were overall considered fit‐for‐purpose, except for the developmental toxicity study in rat (data gap); this was considered an issue that could not be finalised since this is a key study to derive the ARfD and the AAOEL. The RMS disagreed with this conclusion.

The toxicological dossier of napropamide‐M is based on studies performed with both napropamide as racemic mixture (50:50 *R*/*S* isomers) and with the *R*‐isomer alone. A comparison of toxicokinetic, acute, short‐term toxicity in rats and genotoxicity studies performed with both substances has determined that they present a similar toxicological profile at equivalent dose levels and it was considered acceptable to bridge between the racemate and the pure *R*‐isomer. Accordingly, when there is no specific study conducted on the *R*‐isomer alone, the available studies performed with the racemic mixture could be considered in the hazard identification and characterisation of napropamide‐M.

Oral absorption of napropamide‐M is not complete (around 70% oral absorption was used to derive the AOEL and AAOEL). The active substance is widely distributed, extensively metabolised (major metabolites being 4‐OGlu‐NOPAM, 4‐OGlu‐NOPA and 4‐Glu‐NPAM) and eliminated, mainly via urine. A residue definition for body fluids and tissues was proposed during the written procedure on additional information assessment as the sum of major metabolites found in the rat metabolism study including the parent active substance.[3](#efs25465-note-1006){ref-type="fn"} A comparative *in vitro* metabolism study has not been submitted and therefore the risk assessment to unique human metabolites cannot be finalised whilst this study is not submitted.

Low acute toxicity was observed when napropamide‐M was administered by the oral, dermal or inhalation routes; no skin or eye irritation, or skin sensitisation potential was attributed to the active substance. No phototoxicity test has been provided for napropamide‐M; therefore, a data gap is identified but it is acknowledged that no validated methods are available to address properly ultraviolet B (UVB) absorbers such as napropamide‐M. This applies to both phototoxicity and photomutagenicity (data gap).

Blood (with signs of regenerative haemolytic anaemia) is the main target organ of the active substance in rats, blood, gastrointestinal tract and kidneys in dogs upon short‐term exposure, and the liver in mice after long‐term administration. The overall critical short‐term no observed adverse effect level (NOAEL) is 50 mg/kg body weight (bw) per day from the 1‐year dog study with napropamide and the 90‐day study in rat with napropamide‐M. It was concluded that napropamide is unlikely to be carcinogenic; however to confirm this conclusion, valid historical control data were required, but not provided by the applicant[4](#efs25465-note-1007){ref-type="fn"} (data gap). The critical long‐term NOAEL is 30 mg/kg bw per day for body weight decrease from the 2‐year rat study. Positive results were obtained with both napropamide and napropamide‐M in *in vitro* gene mutation assays with metabolic activation; these results were not reproduced *in vivo* in a comet assay with napropamide‐M. Accordingly, the active substance is unlikely to be genotoxic *in vivo*.

No adverse effects were observed on the reproduction or fertility in a three‐generation reproductive toxicity study conducted in 1978, prior to Good Laboratory Practice (GLP) and OECD guidelines. Regarding the developmental toxicity, abortions were observed in rabbits with a NOAEL of 300 mg/kg bw per day. In rats, early maternal reduction of body weight was seen with a NOAEL of 110 mg/kg bw per day. No neurotoxic or immunotoxic potential were attributed to the active substance. Napropamide‐M is not classified or proposed to be classified as carcinogenic or toxic for reproduction category 2; on this basis, the conditions of the interim provisions of Annex II, Point 3.6.5 of Regulation (EC) No 1107/2009 concerning human health for the consideration of endocrine‐disrupting (ED) properties are not met. From a scientific perspective, an endocrine‐mediated mode of action cannot be excluded considering the effects observed in apical studies, such as non‐statistically significant increase in prostate gland carcinomas, mammary gland adenocarcinomas and benign adrenal pheochromocytomas in the 2‐year rat study at the top dose of 522 mg/kg bw per day (data gap for valid historical control data). Considering also that within the three‐generation reproductive toxicity study, sensitive parameters for the ED assessment have not been investigated and that the US EPA data that include *in vitro* tests for androgenic (AR), oestrogenic (ER) or thyroid (ThR) and *in vivo* data from the overall toxicological data package are not fully negative, a potential for ED‐mediated adverse effects cannot be ruled out. A data gap is identified; the issue cannot be finalised.

Toxicological information has been provided on the metabolite NOPA, showing that the metabolite is of low acute toxicity and unlikely to be genotoxic. Published literature data have been retrieved by the applicant on the metabolites *o*‐phthalic acid, 1‐naphthol and 2‐hydroxy‐1,4‐naphthoquinone (HNQ), but were not summarised in the DAR. It was noted that these publications may be relevant if a toxicological assessment would be needed on these metabolites in the residue or environmental fate and behaviour assessments. It was also noted that toxicological data may become necessary on the metabolites DE‐NPAM, NOPAM, NOPA and 5‐OH‐NPAM (including their genotoxicity profile) for potential other uses that are currently not representative (see Section [3](#efs25465-sec-0008){ref-type="sec"}).

The ADI of napropamide‐M is 0.3 mg/kg bw per day based on the NOAEL of 30 mg/kg bw per day for reduced body weight from the 2‐year rat study and applying an uncertainty factor (UF) of 100[5](#efs25465-note-1008){ref-type="fn"} ; this value is supported by the parental and offspring\'s NOAEL from the three‐generation reproductive toxicity study. The AOEL is 0.35 mg/kg bw per day based on the NOAEL of 50 mg/kg bw per day from the 1‐year dog study, supported by the 90‐day rat study, applying an UF of 100 and correction for limited oral absorption of 70%.[6](#efs25465-note-1009){ref-type="fn"} The ARfD is 1.1 mg/kg bw based on the developmental toxicity study in rats with a maternal NOAEL of 110 mg/kg bw per day for early reduction of maternal body weight, and applying an UF of 100.[7](#efs25465-note-1010){ref-type="fn"} The AAOEL is 0.8 mg/kg bw on the same basis as the ARfD, applying a correction factor of 70% for limited oral absorption.

Regarding the representative formulation, D‐Devrinol 450 SC, a suspension concentrate formulation containing 450 g napropamide‐M per litre, dermal absorption was established at 0.6% for the concentrated formulation and 18% for a spray dilution of 1.3 g/L based on *in vitro* dermal absorption study on human skin. For the representative uses, the estimated operator exposure does not exceed the AOEL or the AAOEL even when no personal protective equipment (PPE) is worn (only workwear) according to the EFSA calculator. The proposed use of the representative formulation is for pre‐emergence application of the crop for which there is no expected re‐entry scenario, therefore a worker exposure assessment was not considered necessary. Estimated bystander and residents' exposure represents at most 9% of the (A)AOEL (as the sum of all pathways for child resident).

3. Residues {#efs25465-sec-0008}
===========

The assessment in the residue section is based on the OECD guidance document on overview of the residue chemistry studies (OECD, [2009](#efs25465-bib-0026){ref-type="ref"}), the OECD publication on the MRL calculations (OECD, [2011](#efs25465-bib-0027){ref-type="ref"}), the European Commission guideline document on the MRL setting (European Commission, [2011](#efs25465-bib-0017){ref-type="ref"}) and the Joint Meeting on Pesticide Residues (JMPR) recommendations on livestock burden calculations (JMPR, [2004](#efs25465-bib-0024){ref-type="ref"}, [2007](#efs25465-bib-0025){ref-type="ref"}).

Napropamide‐M was discussed in the Pesticides Peer Review Experts' Teleconference 182 on residues in June 2018.

Metabolism studies on primary crops were conducted with napropamide (racemate) (cabbage, tomato, potato, rape seed, apples), or napropamide‐M (cabbage, rape seed). Although for some studies the application time was not in line with the application time of the representative GAPs (post‐emergence vs pre‐emergence application), all the studies were considered reliable to depict the metabolism of napropamide‐M in plants. A similar metabolic pattern between napropamide and napropamide‐M was observed, being extensively metabolised, with formation of several metabolites, DE‐NPAM, NOPAM, NOPA, 5‐OH‐NPAM, all below 10% of the total radioactive residues (TRRs). Despite the low level of napropamide and napropamide‐M residues (max. 1.1% of TRRs in potato peels and 0.3% of TRRs in cabbage whole plant), the agreed **residue definition for monitoring and risk assessment** was **napropamide (sum of** ***S*** **‐ and** ***R*** **‐isomers)** limited to the representative uses. For potential future uses resulting in a higher exposure for consumers of the metabolites DE‐NPAM, NOPAM, NOPA and 5‐OH‐NPAM, their toxicity should be addressed and their potential inclusion in the residue definition for risk assessment should be reconsidered.

The confined rotational metabolism studies were conducted with napropamide labelled in cereals (wheat), root/tuber (carrot) and leafy (lettuce) crops at the rate of 4.80 kg/ha at 60, 180 and 364 days plant‐back intervals (PBIs). It was noted that the TRRs declined from the first to the third PBI from 1.85 mg/kg to 0.78 mg/kg in wheat straw, while in wheat grain the residue level increased slightly from 0.1 mg/kg to 0.11 mg/kg. Napropamide and DE‐NPAM were the major components in the rotational crop studies in all investigated crops, except wheat grain where no significant metabolites were identified; napropamide accounted for up to 36% TRRs in carrot roots while DE‐NPAM accounted for up to 20% TRRs in carrot top. No identification was possible in wheat grains at any PBI, since the major part of the radioactivity was incorporated into natural plant constituents and all the fractions for characterisation were recovered at a level \< 0.01 mg/kg.

Five wheat rotational field trials were submitted. These were conducted following the harvesting of the oilseed rape and they were analysed for napropamide residues only. All napropamide levels were below 0.01 mg/kg, except one sample of immature plant where the level was 0.04 mg/kg. However, the residue levels in the soil at planting stage were not known, and cannot be compared with the maximum predicted environmental concentration in soil (PEC~soil~); therefore additionally four rotational field trials analysing for napropamide‐M and DE‐NPAM and covering the max. PEC~soil~ are needed in root crops (data gap). If it turns out that quantifiable residues of DE‐NPAM are observed, the toxicity of this compound should be addressed and the residue definition for rotational crops reconsidered. Currently, the residue definitions derived for primary crops are applicable also for succeeding crops.

These data are also needed to confirm whether the MRL proposal for rotational crops is triggered. It should be noted that, pending on the outcome of the requested rotational field trials, further investigation of the processed commodities and livestock might be triggered.

Sufficient residue trials were submitted on flower‐head brassicas (cabbage, Brussels sprout, cauliflower) and oilseed rape validated by the analytical method, however for flower‐head brassica trials, the stability of the residues was not demonstrated; therefore, the MRL of 0.01[\*](#efs25465-note-1800){ref-type="fn"} mg/kg will be proposed in rapeseed only. For leafy brassicas, no residue trials were submitted and they are requested (data gap).

Storage stability studies were conducted with napropamide in high water and high oil content commodities and with napropamide‐M in high acid content commodities. The ones conducted in high water are not acceptable since no information at the day 'zero' was submitted and the first analysis was performed after 7 months of storage (data gap). For rapeseed and grapes, the stability of residues was demonstrated for at least 12 months.

Hydrolysis studies for napropamide were not available and not required for the time being due to the level of residues (\< 0.01 mg/kg).

Livestock metabolism studies were provided, although not triggered. They were conducted with napropamide (no bridging studies were provided) in laying hens at dosing level of 0.57 mg/kg bw per day for 10 days and in lactating goats at the level of 0.29 mg/kg bw per day for 4 days. Since up to 92% of the radioactivity was excreted, the TRRs extracted in different animal tissues were limited (max. 0.105 mg/kg in poultry liver and 0.17 mg/kg in ruminants' liver). Napropamide was extensively metabolised with formation of several metabolites, all below 0.01 mg/kg, except NOPA accounting for 14% (0.013 mg/kg) of TRRs in poultry liver. For ruminants liver, only 19% of the TRRs was easily extracted. After further attempts, it was concluded that any metabolites were minor metabolites (\< 0.01 mg/kg), and that 40% of the TRR radioactivity was associated with precipitated proteins. In all the other animal tissues, the total TRRs were less than 0.05 mg/kg; therefore, further investigation was either not needed or the level of identified metabolites was less than 0.01 mg/kg. Currently, residue definitions could not be proposed for animal commodities and they are not necessary for the representative uses. Fish metabolism studies are not necessary since the estimated dietary intake is not expected to exceed 0.1 mg/kg dry matter (DM).

A consumer risk assessment using the EFSA Pesticide Residues Intake model (PRIMo) rev.2 model was conducted for rapeseed only, since for brassica no valid storage stability data were available. The chronic and acute dietary intakes were all below the ADI and ARfD for all considered European consumer groups (less than 0.01% of the ADI and ARfD).

Since the overall residue level in primary cops assessed for the representative uses was less than 0.01 mg/kg, no further data on the level of residues in pollen and bee products would be required. However, due to the persistence of napropamide‐M in the soil (up to 1,000 days) and the missing data on the level of residues in the succeeding crops, data on the magnitude of residues in pollen and bee products for human consumption covering also rotational crops are needed (data gap). It should be noted that the RMS does not support this data gap.

The consumer risk assessment from the consumption of drinking water is also not finalised considering the lack of appropriate information to address the effect of water treatment processes on the nature of residues of the active substance and its possible metabolites, potentially present in surface water, when surface water is abstracted for drinking water (see Section [4](#efs25465-sec-0009){ref-type="sec"}).

4. Environmental fate and behaviour {#efs25465-sec-0009}
===================================

Napropamide‐M was discussed at the Pesticides Peer Review Experts' Teleconference 180 (June 2018).

The methods of analysis used in all the environmental fate and behaviour studies were stereoselective. It was concluded that napropamide‐M remained as the *R*‐isomer throughout all environmental fate radiolabelled studies and no isomerisation to the *S*‐form occurred. The rates of dissipation and degradation in the environmental matrices investigated were estimated using FOCUS ([2006](#efs25465-bib-0022){ref-type="ref"}) kinetics guidance.

The available information was not sufficient to address the route of degradation of napropamide‐M in soil under aerobic conditions. Consequently, the risk assessment to soil and aquatic organisms and the groundwater exposure for any transformation products that might be formed from napropamide‐M in soil is not finalised. In anaerobic soil incubations napropamide‐M was essentially stable. Napropamide‐M exhibited medium to low mobility in soil. It was concluded that the adsorption of napropamide‐M was not pH dependent. Satisfactory field dissipation studies were carried out at four European locations (Italy, Spain, Germany and the UK), where both spring and autumn trials were conducted. Under field conditions napropamide‐M exhibited moderate to very high persistence. Field study DT~50~ values were accepted as being reasonable estimates of degradation and were normalised to FOCUS reference conditions (20°C and pF2 soil moisture) using the time step normalisation procedure in accordance with FOCUS ([2006](#efs25465-bib-0022){ref-type="ref"}) kinetics guidance. Napropamide‐M is considered to be photolytically stable in soil.

In laboratory incubations in dark aerobic natural sediment water systems, napropamide‐M exhibited high persistence. No major transformation products were detected in the surface water or in the sediment extracts. Non‐extracted residues formed a maximum of 12.2% applied radioactivity (AR) and mean CO~2~ formation was \< 0.1% AR for both test systems. Napropamide‐M in irradiated samples of a laboratory sterile aqueous photolysis experiment degraded completely within the study duration (120 min), whereas there was no degradation in the dark controls. Three major photolytic metabolites \> 10% AR were formed: isomer I (max. 37% AR), isomer II (max. 57% AR) and 1‐naphthol (max. 23% AR).

The necessary surface water and sediment exposure assessments (PEC calculations) were carried out for napropamide‐M using the FOCUS step 3 (FOCUS, [2001](#efs25465-bib-0021){ref-type="ref"}) and step 4 calculations.[8](#efs25465-note-1011){ref-type="fn"} The step 4 calculations appropriately followed the FOCUS ([2007](#efs25465-bib-0023){ref-type="ref"}) guidance, with no‐spray drift buffer zones of up to 20 m being implemented for the drainage scenarios (representing \< 95% spray drift reduction), and combined no‐spray buffer zones with vegetative buffer strips of up to 20 m (reducing solute flux in run‐off by 80% and erosion run‐off of mass adsorbed to soil by 95%) being implemented for the run‐off scenarios. The SWAN tool (version 4.0.1) was appropriately used to implement these mitigation measures in the simulations. However, risk managers and others may wish to note that whilst run‐off mitigation is included in the step 4 calculations available, the FOCUS ([2007](#efs25465-bib-0023){ref-type="ref"}) report acknowledges that for substances with K~Foc~ \< 2,000 mL/g (i.e. napropamide‐M), the general applicability and effectiveness of run‐off mitigation measures had been less clearly demonstrated in the available scientific literature, than for more strongly adsorbed compounds. The PEC~SW~ values for the photolytic metabolites isomer I, isomer II and 1‐naphthol were calculated from the maximum percentage of each metabolite detected and an adjustment for the difference in molecular weight between the parent napropamide‐M and each compound. The metabolites were modelled based on the parent PEC~sw~ values at step 3.

The necessary groundwater exposure assessments were appropriately carried out using FOCUS (European Commission, [2014](#efs25465-bib-0020){ref-type="ref"}) scenarios and the models PEARL 4.4.4, PELMO 5.5.3 and MACRO 5.5.4.[8](#efs25465-note-1011){ref-type="fn"} The potential for groundwater exposure from the representative uses by napropamide‐M above the parametric drinking water limit of 0.1 μg/L was concluded to be low in geoclimatic situations that are represented by all nine FOCUS groundwater scenarios.

The applicant did not provide appropriate information to address the effect of water treatment processes on the nature of the residues that might be present in surface water, when surface water is abstracted for drinking water. This has led to the identification of a data gap (see Section [7](#efs25465-sec-0012){ref-type="sec"}) and results in the consumer risk assessment not being finalised (see Section [9](#efs25465-sec-0014){ref-type="sec"}).

The PEC in soil, surface water, sediment and groundwater covering the representative uses assessed can be found in Appendix [A](#efs25465-sec-1002){ref-type="sec"} of this conclusion.

5. Ecotoxicology {#efs25465-sec-0010}
================

The risk assessment was based on the following documents: European Commission ([2002a](#efs25465-bib-0012){ref-type="ref"},[b](#efs25465-bib-0013){ref-type="ref"}), SETAC ([2001](#efs25465-bib-0028){ref-type="ref"}), EFSA ([2009](#efs25465-bib-0003){ref-type="ref"}), EFSA PPR Panel ([2013](#efs25465-bib-0009){ref-type="ref"}) and EFSA ([2013](#efs25465-bib-0006){ref-type="ref"}). Napropamide‐M was discussed at the Pesticides Peer Review Experts' meeting 181 in June 2018.

Pending on the data gap identified in Section [4](#efs25465-sec-0009){ref-type="sec"} on the route of degradation in soil of napropamide‐M, further ecotoxicological assessments of metabolites might be necessary to address the potential risk to birds and mammals (when exposed to soil metabolites if translocated into the plant and via secondary poisoning), aquatic and soil organisms and honeybees.

No information was available to support the compliance of one of the batches (UPH‐08/DNE‐263/TECH/20121009) used in two ecotoxicological studies with the technical specification, in particular with regard to the content of [d]{.smallcaps}‐isomer (data gap).

Based on the available data, a low acute and long‐term risk to **birds** for napropamide‐M was concluded for all routes of exposure and for all the representative uses. It has to be noted that no chronic data were available with napropamide‐M. The only available chronic data were on napropamide. However, considering the available acute data on both substances showing comparable toxicity and the similar molecular structure, the extrapolation was supported. In addition, a low risk was identified at the screening step of the assessment.

A low acute and long‐term risk to **mammals** for napropamide‐M was concluded for all routes of exposure and for all the representative uses, except for earthworm‐eating mammals. The use of a refined PEC~soil~ based on a 20‐cm tillage depth was not considered appropriate.[9](#efs25465-note-1012){ref-type="fn"} However, considering that the TER calculation was very close to the trigger (4.8) and in addition, the lowest KFoc was used instead of the geomean Freundlich organic carbon adsorption coefficient (KFoc), a low risk to earthworm‐eating mammals was also concluded.

A low risk was concluded for fish‐eating **birds** and **mammals** for napropamide‐M metabolites napropamide isomer I and napropamide isomer II.

Toxicity data were available on the relevant **aquatic taxa**. The available chronic study with fish was discussed at the Pesticides Peer Review Experts' meeting 181. Due to the deficiencies in the study design and in the performance of the control, the study was considered unreliable (data gap). From the available information, it was, however, clear that fish are not the main driver of the risk assessment, as aquatic macrophytes were the most sensitive organisms.

Based on the available data, a low risk to **fish** (acute), **aquatic invertebrates** (acute) and **algae** was concluded for all the representative uses. A low chronic risk to **aquatic invertebrates** and **aquatic macrophytes** was concluded for napropamide‐M provided that mitigation measures up to 20 m buffer zone and 20 m vegetative filter strip are implemented for all the representative uses, except for situations represented by the scenario D2 for the use on winter oil seed rape (data gap).

Based on a screening assessment, a low risk to **aquatic organisms** was concluded for the pertinent metabolites isomer I and isomer II for the representative use on brassica vegetable crops. For the representative use on winter oilseed rape, high risk could not be excluded to aquatic invertebrates in situations represented by the D2 scenario even after the implementation of risk mitigation measures. For the pertinent metabolite 1‐naphthol, a high risk could not be excluded to aquatic invertebrates for the D2 scenario (representative use on winter oil seed rape) and the R3 and R4 scenarios (representative use on brassica vegetable crops) and for aquatic plants for all of the relevant FOCUS scenarios for all uses (data gap).

Suitable acute (oral and contact) and chronic (adult and larvae) toxicity studies on honey**bees** were available. A risk assessment in line with the Guidance Document on Terrestrial Ecotoxicology (European Commission, [2002a](#efs25465-bib-0012){ref-type="ref"}) was provided which demonstrated a low acute (contact and oral) risk to honeybees for all the representative uses. It is, however, noted that the presented assessment does not cover an assessment of the chronic risk to honeybee larvae and adults. Therefore, a data gap was identified for a risk assessment in line with EFSA ([2013](#efs25465-bib-0006){ref-type="ref"}) for napropamide‐M and for any metabolites potentially formed in pollen and nectar. An assessment to address the risk via exposure to contaminated water was not performed (data gap). An assessment for potential sublethal effects for honeybees (e.g. effect on hypopharyngeal glands (HPG)) was not provided (data gap). An assessment of potential accumulative effects was not available. No data were available on bumblebees or solitary bees.

Tier I toxicity studies with **non‐target arthropods** have been conducted with the representative formulation. Based on those data, low risk was identified at Tier I. Even though napropamide‐M did not exhibit very high effects on mortality, those studies indicated effects higher than 50% on the reproduction of the two standard species. To further elucidate those effects on reproduction, only an extended laboratory study with the species *Aphidius rhopalosiphi* was submitted and therefore a data gap was identified.

A low risk for napropamide‐M to **earthworms** and other **soil organisms** as well as **to soil microorganisms** was concluded for all the representative uses.

For **non‐target terrestrial plants**, low risk was concluded with the implementation of mitigation measures up to 5 m buffer zone.

A low risk for napropamide‐M to organisms used in **biological methods of sewage treatment** was concluded for all the representative uses.

Pending on the data gap identified in Section [2](#efs25465-sec-0007){ref-type="sec"}, further ecotoxicological data may be needed to draw a firm conclusion on the endocrine disruption potential of napropamide‐M on non‐target organisms other than mammals.

6. Overview of the risk assessment of compounds listed in residue definitions triggering assessment of effects data for the environmental compartments (Tables [1](#efs25465-tbl-0001){ref-type="table"}, [2](#efs25465-tbl-0002){ref-type="table"}, [3](#efs25465-tbl-0003){ref-type="table"}, [4](#efs25465-tbl-0004){ref-type="table"}) {#efs25465-sec-0011}
==========================================================================================================================================================================================================================================================================================================================================

###### 

Soil

+----------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------+
| Compound (name and/or code)                                                                                                                        | Persistence                                                                                                                                               | Ecotoxicology                 |
+====================================================================================================================================================+===========================================================================================================================================================+===============================+
| Napropamide‐M                                                                                                                                      | Moderate to very high persistence                                                                                                                         | Low risk                      |
|                                                                                                                                                    |                                                                                                                                                           |                               |
|                                                                                                                                                    | European field dissipation studies single first‐order and biphasic soil DT~50~ 13--1,000 days (20°C pF 2 soil moisture; actual DT~90~ 135--\> 1,000 days) |                               |
+----------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------+
| Open for potential metabolites that could be formed at levels that trigger further assessment due to data gap for the route of degradation in soil | Open                                                                                                                                                      | Data gap for soil metabolites |
+----------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------+

DT~50~: period required for 50% dissipation; DT~90~: period required for 90% dissipation.

John Wiley & Sons, Ltd

###### 

Groundwater

+----------------------------------------------------------------------------------------------------------------------------------------------------+------------------------+---------------------------------------------------------------------------------------------+---------------------+----------------------------------------------------+
| Compound (name and/or code)                                                                                                                        | Mobility in soil       | \> 0.1 μg/L at 1 m depth for the representative uses[a](#efs25465-note-0006){ref-type="fn"} | Pesticidal activity | Toxicological relevance                            |
+====================================================================================================================================================+========================+=============================================================================================+=====================+====================================================+
| Napropamide‐M                                                                                                                                      | Medium to low mobility | No                                                                                          | Yes                 | Yes                                                |
|                                                                                                                                                    |                        |                                                                                             |                     |                                                    |
|                                                                                                                                                    | K~Foc~ 313--747 mL/g   |                                                                                             |                     |                                                    |
+----------------------------------------------------------------------------------------------------------------------------------------------------+------------------------+---------------------------------------------------------------------------------------------+---------------------+----------------------------------------------------+
| Open for potential metabolites that could be formed at levels that trigger further assessment due to data gap for the route of degradation in soil | Open                   | Open                                                                                        | Open                | Data may be needed pending on the final assessment |
+----------------------------------------------------------------------------------------------------------------------------------------------------+------------------------+---------------------------------------------------------------------------------------------+---------------------+----------------------------------------------------+

K~Foc~: Freundlich organic carbon adsorption coefficient.

At least one FOCUS scenario or a relevant lysimeter.

John Wiley & Sons, Ltd

###### 

Surface water and sediment

  Compound (name and/or code)                                                                                                                          Ecotoxicology
  ---------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------
  Napropamide‐M                                                                                                                                        High risk to aquatic organisms in 1 out of 6 scenarios for winter oil seed rape (data gap). Low risk for the use in brassica vegetable crops
  Isomer I                                                                                                                                             High risk to aquatic organisms in 1 out of 6 scenarios for winter oil seed rape (data gap). Low risk for the use in brassica vegetable crops
  Isomer II                                                                                                                                            High risk to aquatic organisms in 1 out of 6 scenarios for winter oil seed rape (data gap). Low risk for the use in brassica vegetable crops
  1‐Napthol                                                                                                                                            High risk to aquatic organisms for most scenarios for all uses (data gap)
  Open for potential metabolites that could be formed at levels that trigger further assessment due to data gap for the route of degradation in soil   Open

John Wiley & Sons, Ltd

###### 

Air

  Compound (name and/or code)                                                                                                                          Toxicology
  ---------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------
  Napropamide‐M                                                                                                                                        Rat LC~50~ inhalation \> 4.8 mg/L air per 4 h (nose‐only) -- study performed on napropamide racemate -- no classification required
  Open for potential metabolites that could be formed at levels that trigger further assessment due to data gap for the route of degradation in soil   Open

LC~50~: lethal concentration, median.

John Wiley & Sons, Ltd

7. Data gaps {#efs25465-sec-0012}
============

This is a list of data gaps identified during the peer review process, including those areas in which a study may have been made available during the peer review process but not considered for procedural reasons (without prejudice to the provisions of Article 56 of the Regulation concerning information on potentially harmful effects). A more detailed assessment of the literature review on the active substance and its relevant metabolites in ecotoxicology (including search terms and applied relevance criteria) in accordance with the EFSA guidance on the submission of scientific peer‐reviewed open literature for the approval of pesticide active substances under Regulation (EC) No 1107/2009 (EFSA, [2011](#efs25465-bib-0005){ref-type="ref"}; relevant for all representative uses evaluated; relevant for Section [5](#efs25465-sec-0010){ref-type="sec"}, [10](#efs25465-note-1013){ref-type="fn"}).Data on oxidising properties of the active substance according to the UN test method for classification (CLP 1272/2008) are missing (relevant for all representative uses evaluated; see Section [1](#efs25465-sec-0006){ref-type="sec"}).Enantioselective monitoring methods for water and air are missing (relevant for all representative uses evaluated; see Section [1](#efs25465-sec-0006){ref-type="sec"}).Analytical methods for monitoring of all components of the residue definition in body fluids and tissues should be provided (relevant for all representative uses evaluated; see Section [1](#efs25465-sec-0006){ref-type="sec"}).Validation of the analytical methods used in the developmental toxicity study in rat (key study to derive the ARfD and AAOEL) is missing (relevant for all representative uses evaluated; see Sections [1](#efs25465-sec-0006){ref-type="sec"} and [2](#efs25465-sec-0007){ref-type="sec"}).An assessment of the toxicological relevance of the individual impurities present in the technical specification in comparison with the toxicological profile of the parent compound, napropamide‐M; impurity profile of the batch used in the *in vivo* comet assay should be clarified (relevant for all representative uses evaluated; see Section [2](#efs25465-sec-0007){ref-type="sec"}).An *in vitro* interspecies comparative metabolism study is missing (relevant for all representative uses evaluated; see Section [2](#efs25465-sec-0007){ref-type="sec"}).The phototoxicity and photomutagenicity potential should be addressed -- being acknowledged that there is currently no validated test guideline to address these issues, in particular for UVB absorbers such as napropamide‐M (relevant for all representative uses evaluated; see Section [2](#efs25465-sec-0007){ref-type="sec"}).Historical control data (HCD) to confirm that the increase in carcinogenic effects observed in the rat 2‐year study such as prostate gland carcinoma and brain astrocytomas in males or adrenal gland benign pheochromocytoma and mammary gland adenocarcinomas in females are not treatment‐related should be provided (relevant for all representative uses evaluated; see Section [2](#efs25465-sec-0007){ref-type="sec"}).Further information to clarify the endocrine‐disrupting potential of napropamide‐M considering the effects observed in the apical studies, such as increase in prostate gland carcinomas, mammary gland adenocarcinomas and benign adrenal pheochromocytomas in the 2‐year rat study at the top dose (see data gap for valid HCD) should be provided. Considering also that within the three‐generation reproductive toxicity study, sensitive parameters for the ED assessment have not been investigated and that the US EPA data that include *in vitro* tests for AR, ER or ThR data package are not fully negative (relevant for all representative uses evaluated; see Section [2](#efs25465-sec-0007){ref-type="sec"}).Storage stability data to support the validity of the residue trials in brassica are required (relevant for the brassica uses; see Section [3](#efs25465-sec-0008){ref-type="sec"}).Sufficient residue trials covered by storage stability and validated analytical method, to support the representative use in leafy brassicas are requested (relevant for the leafy brassica uses; see Section [3](#efs25465-sec-0008){ref-type="sec"}).Four rotational field trials covering the max. PEC~soil~ in root crops and analysing for napropamide‐M and metabolite DE‐NPAM are required (relevant for all representative uses evaluated; see Section [3](#efs25465-sec-0008){ref-type="sec"}).Data on the magnitude of residues in pollen and bee products for human consumption covering also rotational crops are required (relevant for all representative uses evaluated; see Section [3](#efs25465-sec-0008){ref-type="sec"}).Reliable route of degradation of napropamide‐M in soil is missing. Pending on this additional information, further ecotoxicological assessments of metabolites might be necessary to address the potential risk to birds and mammals (when exposed to soil metabolites if translocated into the plant and via secondary poisoning), aquatic and soil organisms and honeybees (relevant for all representative uses evaluated; see Sections [4](#efs25465-sec-0009){ref-type="sec"} and [5](#efs25465-sec-0010){ref-type="sec"}).An assessment of the effect of water treatment processes on the nature of residues present in surface water, when surface water is abstracted for drinking water is not available. In the first instance, a consideration of the processes of ozonation and chlorination would appear appropriate. If an argumentation is made that concentrations at the point of abstraction for drinking water purposes will be low, this argumentation should cover metabolites predicted to be in surface water as well as the active substance. Should this consideration indicate novel compounds might be expected to be formed from water treatment, the risk to human or animal health through the consumption of drinking water containing them should be addressed (relevant for all representative uses evaluated; see Sections [3](#efs25465-sec-0008){ref-type="sec"} and [4](#efs25465-sec-0009){ref-type="sec"}).Satisfactory evidence to support the identification of the dimer found in the study on aerobic mineralisation in surface water should be provided (data gap not relevant to finalise the risk assessment for the representative uses; see Evaluation Table, data requirement 4.2 in EFSA, [2018](#efs25465-bib-0007){ref-type="ref"}).Further information to support the compliance of one of the batch (UPH‐08/DNE‐263/TECH/20121009) used in two ecotoxicological studies with the technical specification, in particular regarding the content in [d]{.smallcaps}‐isomer (relevant for all representative uses; see Section [5](#efs25465-sec-0010){ref-type="sec"}).Further chronic data on fish for napropamide‐M are missing (relevant for all representative uses; see Section [5](#efs25465-sec-0010){ref-type="sec"}).Further information to address the chronic risk to aquatic organisms is missing (in particular invertebrates and plants) for napropamide‐M and isomer I and isomer II for the FOCUS D2 scenario (relevant for the representative use on winter oil seed rape; see Section [5](#efs25465-sec-0010){ref-type="sec"}).Further information to address the risk to aquatic organisms is missing (in particular invertebrates and plants) for 1‐naphthol for the majority of the relevant FOCUS scenarios (relevant for all representative uses; see Section [5](#efs25465-sec-0010){ref-type="sec"}).A risk assessment to bees according to EFSA ([2013](#efs25465-bib-0006){ref-type="ref"}) relevant for napropamide‐M and its metabolites, including the risk assessment via contaminated water and for sublethal effects is missing (relevant for all representative uses; see Section [5](#efs25465-sec-0010){ref-type="sec"}).Further data to elucidate the effects on reproduction of non‐target arthropods are missing (relevant for all representative uses; see Section [5](#efs25465-sec-0010){ref-type="sec"}).

8. Particular conditions proposed to be taken into account to manage the risk(s) identified {#efs25465-sec-0013}
===========================================================================================

For the representative use on brassica vegetable crops, mitigation measures up to 20 m buffer zone and 20 m vegetative filter strip are needed to resolve the risk to **aquatic macrophytes** for the scenarios D3, D6, R1, R3 and R4. For concluding low risk to aquatic invertebrates, mitigation measures comparable to 10 m buffer zone and 10--12 m vegetative filter strip are needed (see Section [5](#efs25465-sec-0010){ref-type="sec"}).For the representative use on winter oil seed rape, a low risk to **aquatic macrophytes** was concluded only with mitigation measures up to 10 m buffer zone and 12 m vegetative filter strip for scenarios D3, D5, R1 and R3 (see Section [5](#efs25465-sec-0010){ref-type="sec"}).Mitigation measures comparable to 5 m buffer zone are needed to conclude on a low risk to non‐target terrestrial plants (see Section [5](#efs25465-sec-0010){ref-type="sec"}).

9. Concerns {#efs25465-sec-0014}
===========

9.1. Issues that could not be finalised {#efs25465-sec-0015}
---------------------------------------

An issue is listed as 'could not be finalised' if there is not enough information available to perform an assessment, even at the lowest tier level, for the representative uses in line with the uniform principles in accordance with Article 29(6) of the Regulation and as set out in Commission Regulation (EU) No 546/2011[11](#efs25465-note-1014){ref-type="fn"} and if the issue is of such importance that it could, when finalised, become a concern (which would also be listed as a critical area of concern if it is of relevance to all representative uses).

An issue is also listed as 'could not be finalised' if the available information is considered insufficient to conclude on whether the active substance can be expected to meet the approval criteria provided for in Article 4 of the Regulation. The *in vitro* interspecies comparative metabolism study is not yet available. The discussion for the need for further tests and risk assessment to unique human metabolites cannot be finalised whilst this study is not submitted (see Section [2](#efs25465-sec-0007){ref-type="sec"}).Analytical methods used in the developmental toxicity study in rats, key study to derive the ARfD and AAOEL is not available, the lack of which put in question the validity of this study and therefore the developmental toxicity endpoint in rat could not be finalised (see Section [2](#efs25465-sec-0007){ref-type="sec"}).The assessment of the ED potential of napropamide‐M cannot be finalised considering the effects observed in the apical studies, such as increase in prostate gland carcinomas, mammary gland adenocarcinomas and benign adrenal pheochromocytomas in the 2‐year rat study at the top dose (see data gap for valid HCD). Considering also that within the three‐generation reproductive toxicity study, sensitive parameters for the ED assessment have not been investigated and that the US EPA data that include *in vitro* tests for AR, ER or ThR data are not fully negative (see Section [2](#efs25465-sec-0007){ref-type="sec"}).The route of degradation of napropamide‐M in soil under aerobic conditions has not been addressed. Consequently, the risk assessment to soil and aquatic organisms and the groundwater exposure for any transformation products that might be formed from napropamide‐M in soil is not finalised for the representative uses (see Sections [4](#efs25465-sec-0009){ref-type="sec"} and [5](#efs25465-sec-0010){ref-type="sec"}).The available information is insufficient to conclude whether napropamide‐M will have no immediate or delayed harmful/effects on human health, including vulnerable groups, or on animal health, through drinking water (taking into account substances resulting from water treatment). Consequently, the consumer risk assessment from the consumption of drinking water could not be finalised (see Sections [3](#efs25465-sec-0008){ref-type="sec"} and [4](#efs25465-sec-0009){ref-type="sec"}).

9.2. Critical areas of concern {#efs25465-sec-0016}
------------------------------

An issue is listed as a critical area of concern if there is enough information available to perform an assessment for the representative uses in line with the uniform principles in accordance with Article 29(6) of the Regulation and as set out in Commission Regulation (EU) No 546/2011, and if this assessment does not permit the conclusion that, for at least one of the representative uses, it may be expected that a plant protection product containing the active substance will not have any harmful effect on human or animal health or on groundwater or any unacceptable influence on the environment.

An issue is also listed as a critical area of concern if the assessment at a higher tier level could not be finalised due to lack of information, and if the assessment performed at the lower tier level does not permit the conclusion that, for at least one of the representative uses, it may be expected that a plant protection product containing the active substance will not have any harmful effect on human or animal health or on groundwater or any unacceptable influence on the environment.

An issue is also listed as a critical area of concern if, in the light of current scientific and technical knowledge using guidance documents available at the time of application, the active substance is not expected to meet the approval criteria provided for in Article 4 of the Regulation. The impurity profile of the batches of napropamide (racemate) used in key studies to derive most of the toxicological reference values (ADI, ARfD and AAOEL) is unknown, and the technical specification is not supported by the toxicological assessment. It is however noted that the technical specification is supported by the batches used to test napropamide‐M (key study to establish the AOEL and to assess the genotoxic potential of the active substance) (see Section [2](#efs25465-sec-0007){ref-type="sec"}).

9.3. Overview of the concerns identified for each representative use considered {#efs25465-sec-0017}
-------------------------------------------------------------------------------

(If a particular condition proposed to be taken into account to manage an identified risk, as listed in Section [8](#efs25465-sec-0012){ref-type="sec"}, has been evaluated as being effective, then 'risk identified' is not indicated in Table [5](#efs25465-tbl-0005){ref-type="table"}.)

All columns are grey, as the technical material specification proposed was not comparable to the material used in the testing that would be used to derive the toxicological reference values (ADI, ARfD and AAOEL).

###### 

Overview of concerns

  Representative use                                                            Winter oilseed rape                                                      Brassica vegetable crops                                                             
  ----------------------------------------------------------------------------- ------------------------------------------------------------------------ -------------------------- --------------------- --------------------- ------ ------ --
  **Operator risk**                                                             Risk identified                                                                                                                                               
  Assessment not finalised                                                                                                                                                                                                                    
  **Worker risk**                                                               Risk identified                                                                                                                                               
  Assessment not finalised                                                                                                                                                                                                                    
  **Resident/bystander risk**                                                   Risk identified                                                                                                                                               
  Assessment not finalised                                                                                                                                                                                                                    
  **Consumer risk**                                                             Risk identified                                                                                                                                               
  Assessment not finalised                                                      X^5^                                                                     X^5^                       X^5^                  X^5^                  X^5^   X^5^   
  **Risk to wild non‐target terrestrial vertebrates**                           Risk identified                                                                                                                                               
  Assessment not finalised                                                                                                                                                                                                                    
  **Risk to wild non‐target terrestrial organisms other than vertebrates**      Risk identified                                                                                                                                               
  Assessment not finalised                                                      X^4^                                                                     X^4^                       X^4^                  X^4^                  X^4^   X^4^   
  **Risk to aquatic organisms**                                                 Risk identified                                                          x (1 out of 6 uses)        x (1 out of 6 uses)   x (1 out of 6 uses)                 
  Assessment not finalised                                                      X^4^                                                                     X^4^                       X^4^                  X^4^                  X^4^   X^4^   
  **Groundwater exposure to active substance**                                  Legal parametric value breached                                                                                                                               
  Assessment not finalised                                                                                                                                                                                                                    
  **Groundwater exposure to metabolites**                                       Legal parametric value breached[a](#efs25465-note-0010){ref-type="fn"}                                                                                        
  Parametric value of 10 μg/L[b](#efs25465-note-0011){ref-type="fn"} breached                                                                                                                                                                 
  Assessment not finalised                                                      X^4^                                                                     X^4^                       X^4^                  X^4^                  X^4^   X^4^   

BBCH: growth stages of mono‐ and dicotyledonous plants.

Columns are grey if no safe use can be identified. The superscript numbers relate to the numbered points indicated in Sections [9.1](#efs25465-sec-0014){ref-type="sec"} and [9.2](#efs25465-sec-0015){ref-type="sec"}. Where there is no superscript number, see Sections [2](#efs25465-sec-0007){ref-type="sec"}, [3](#efs25465-sec-0008){ref-type="sec"}, [4](#efs25465-sec-0009){ref-type="sec"}, [5](#efs25465-sec-0010){ref-type="sec"}--[6](#efs25465-sec-0018){ref-type="sec"} for further information.

Based on classification made in the context of this evaluation procedure under Regulation (EC) No 1107/2009. It should be noted that harmonised classification and labelling is formally proposed and decided in accordance with Regulation (EC) No 1272/2008.

Value for non‐relevant metabolites prescribed in SANCO/221/2000‐rev. 10 final, European Commission, [2003](#efs25465-bib-0014){ref-type="ref"}.

John Wiley & Sons, Ltd

Abbreviations {#efs25465-sec-0018}
=============

AAOELacute acceptable operator exposure levelADIacceptable daily intakeAOELacceptable operator exposure levelARapplied radioactivityARandrogenicARfDacute reference doseBBCHgrowth stages of mono‐ and dicotyledonous plantsbwbody weightCLconfidence limitsCLPclassification, labelling and packagingDARdraft assessment reportDMdry matterDT~50~period required for 50% dissipation (define method of estimation)DT~90~period required for 90% dissipation (define method of estimation)ECHAEuropean Chemicals AgencyEDendocrine disruptorEECEuropean Economic CommunityERoestrogenicFAOFood and Agriculture Organization of the United NationsFOCUSForum for the Co‐ordination of Pesticide Fate Models and their UseGAPGood Agricultural PracticeGLPGood Laboratory PracticeGMgeometric meanHCDhistorical control dataHNQ2‐hydroxy‐1,4‐naphthoquinoneHPGhypopharyngeal glandsInChiKeyInternational Chemical Identifier Key.ISOInternational Organization for StandardizationIUPACInternational Union of Pure and Applied ChemistryJMPRJoint Meeting on the FAO Panel of Experts on Pesticide Residues in Food and the Environment and the WHO Expert Group on Pesticide Residues (Joint Meeting on Pesticide Residues)K~Foc~Freundlich organic carbon adsorption coefficientLCliquid chromatographyLC~50~lethal concentration, medianLC--MS/MSliquid chromatography with tandem mass spectrometryLOQlimit of quantificationMRLmaximum residue levelNOAELno observed adverse effect levelNOPAnaphthoxypropionic acidOECDOrganisation for Economic Co‐operation and DevelopmentPECpredicted environmental concentrationPEC~air~predicted environmental concentration in airPEC~gw~predicted environmental concentration in groundwaterPEC~sed~predicted environmental concentration in sedimentPEC~soil~predicted environmental concentration in soilPEC~sw~predicted environmental concentration in surface waterPPEpersonal protective equipmentQuEChERSQuick Easy Cheap Effective Rugged and SafeRMSrapporteur Member StateSCsuspension concentrateSMILESsimplified molecular‐input line‐entry systemTERtoxicity exposure ratioThRthyroidTRRtotal radioactive residueUVultravioletUVBultraviolet BWHOWorld Health Organization

Appendix A -- List of end points for the active substance and the representative formulation {#efs25465-sec-1002}
============================================================================================

 {#efs25465-sec-0019}

Appendix [A](#efs25465-sec-1002){ref-type="sec"} can be found in the online version of this output ('Supporting information' section): <https://doi.org/10.2903/j.efsa.2018.5465>

Appendix B -- Used compound codes {#efs25465-sec-1003}
=================================

 {#efs25465-sec-0020}

Code/trivial name[a](#efs25465-note-1016){ref-type="fn"}IUPAC name/SMILES notation/InChiKey[b](#efs25465-note-1017){ref-type="fn"}Structural formula[b](#efs25465-note-1017){ref-type="fn"}**Napropamide‐M**(*R*)‐*N,N*‐diethyl‐2‐(1‐naphthyloxy)propionamide C\[C@\@H\](OC1=C2C=CC=CC2=CC=C1)C(N(CC)CC)=O WXZVAROIGSFCFJ‐CYBMUJFWSA‐N![](EFS2-16-e05465-g001.jpg "image")**Napropamide**(*RS*)‐*N*,*N*‐diethyl‐2‐(1‐naphthyloxy)propionamide CC(OC1=C2C=CC=CC2=CC=C1)C(N(CC)CC)=O WXZVAROIGSFCFJ‐UHFFFAOYSA‐N![](EFS2-16-e05465-g002.jpg "image")**NOPA** (naphthoxypropionic acid)2‐(naphthalen‐1‐yloxy)propanoic acid CC(OC1=C2C=CC=CC2=CC=C1)C(O)=O KTAVXDDWEGVLRN‐UHFFFAOYSA‐N![](EFS2-16-e05465-g003.jpg "image")**DE‐NPAM** (desethyl napropamide)*N*‐ethyl‐2‐(naphthalen‐1‐yloxy)propanamide CC(OC1=C2C=CC=CC2=CC=C1)C(NCC)=O ZYSGLIDSUFDSLC‐UHFFFAOYSA‐N![](EFS2-16-e05465-g004.jpg "image")**NOPAM**2‐(naphthalen‐1‐yloxy)propanamide CC(OC1=C2C=CC=CC2=CC=C1)C(N)=O WYJKJOYWHVMPFL‐UHFFFAOYSA‐N![](EFS2-16-e05465-g005.jpg "image")**5‐OH‐NPAM***N*,*N*‐diethyl‐2‐((5‐hydroxynaphthalen‐1‐yl)oxy)propanamide CC(OC1=C2C=CC=C(O)C2=CC=C1)C(N(CC)CC)=O STPHPANGOJBKNK‐UHFFFAOYSA‐N![](EFS2-16-e05465-g006.jpg "image")**4‐OGlu‐NOPAM**4‐\[(1‐amino‐1‐oxopropan‐2‐yl)oxy\]naphthalen‐1‐yl *D*‐glucopyranosiduronic acid NC(C(Oc(ccc1OC2O\[C\@H\](C(O)=O)\[C\@H\](\[C@\@H\](\[C\@H\]2O)O)O)c3c1cccc3)C)=O MTQUHYUJTBRWLG‐FVNSOWSRSA‐N![](EFS2-16-e05465-g007.jpg "image")**4‐OGlu‐NOPA**4‐(1‐carboxyethoxy)naphthalen‐1‐yl *D*‐glucopyranosiduronic acid O=C(C(Oc(ccc1OC2O\[C\@H\](C(O)=O)\[C\@H\](\[C@\@H\](\[C\@H\]2O)O)O)c3c1cccc3)C)O DLGDRVAUZOMPMV‐FVNSOWSRSA‐N![](EFS2-16-e05465-g008.jpg "image")**4‐Glu‐NPAM**4‐{\[1‐(diethylamino)‐1‐oxopropan‐2‐yl\]oxy}naphthalen‐1‐yl *D*‐glucopyranosiduronic acid O\[C\@H\](\[C\@H\](\[C@\@H\](\[C@\@H\](C(O)=O)O1)O)O)C1OC2=C3C=CC=CC3=C(OC(C)C(N(CC)CC)=O)C=C2 GCVUHYWGOYVBAA‐XWDSXZHRSA‐N![](EFS2-16-e05465-g009.jpg "image")***o*** **‐phthalic acid**phthalic acid O=C(O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ‐UHFFFAOYSA‐N![](EFS2-16-e05465-g010.jpg "image")**1‐naphthol**naphthalen‐1‐o OC1=C2C=CC=CC2=CC=C1 KJCVRFUGPWSIIH‐UHFFFAOYSA‐N![](EFS2-16-e05465-g011.jpg "image")**Isomer I***N*,*N*‐diethyl‐2‐(4‐hydroxynaphthalen‐1‐yl)propanamide CC(C1=C2C=CC=CC2=C(O)C=C1)C(N(CC)CC)=O IRIXTOKMRDICPB‐UHFFFAOYSA‐N![](EFS2-16-e05465-g012.jpg "image")**Isomer II***N*,*N*‐diethyl‐2‐(1‐hydroxynaphthalen‐2‐yl)propanamide CC(C1=CC=C2C=CC=CC2=C1O)C(N(CC)CC)=O HDMUUPCWKVRTPN‐UHFFFAOYSA‐N![](EFS2-16-e05465-g013.jpg "image")**2‐hydroxy‐1,4‐naphthoquinone (HNQ)**2‐hydroxynaphthalene‐1,4‐dione O=C(C1=C2C=CC=C1)C=C(O)C2=O CSFWPUWCSPOLJW‐UHFFFAOYSA‐N![](EFS2-16-e05465-g014.jpg "image")[^1][^2][^3]

Supporting information
======================

###### 

List of end points for the active substance and the representative formulation

###### 

Click here for additional data file.

Regulation (EC) No 1107/2009 of 21 October 2009 of the European Parliament and of the Council concerning the placing of plant protection products on the market and repealing Council Directives 79/117/EEC and 91/414/EEC. OJ L 309, 24.11.2009, p. 1--50.

See Evaluation Table, data requirement point 5.13 in EFSA ([2018](#efs25465-bib-0007){ref-type="ref"}).

See Evaluation Table, data requirement 2.15 (EFSA, [2018](#efs25465-bib-0007){ref-type="ref"}).

See Evaluation Table, open point 2.9 (EFSA, [2018](#efs25465-bib-0007){ref-type="ref"}).

The same ADI as established for napropamide (EFSA, [2010](#efs25465-bib-0004){ref-type="ref"}; European Commission, [2010b](#efs25465-bib-0016){ref-type="ref"}).

The AOEL set for napropamide was 0.5 mg/kg bw per day (same basis as the AOEL set for napropamide‐M), oral absorption has been revised in the present assessment to 70%, this should apply to napropamide as well.

No ARfD has been set for napropamide, this should be revised and the same ARfD should be set for both substances, napropamide and napropamide‐M.

Simulations utilised the agreed Q10 of 2.58 (following EFSA, [2008](#efs25465-bib-0002){ref-type="ref"}) and Walker equation coefficient of 0.7.

See point 5.1 of the Evaluation table in EFSA, [2018](#efs25465-bib-0007){ref-type="ref"}.

See Evaluation Table, data requirement point 5.13 in EFSA, [2018](#efs25465-bib-0007){ref-type="ref"}.

Commission Regulation (EU) No 546/2011 of 10 June 2011 implementing Regulation (EC) No 1107/2009 of the European Parliament and of the Council as regards uniform principles for evaluation and authorisation of plant protection products. OJ L 155, 11.6.2011, p. 127--175.

MRL is proposed at the LOQ.

[^1]: IUPAC: International Union of Pure and Applied Chemistry; SMILES: simplified molecular‐input line‐entry system; InChiKey: International Chemical Identifier Key.

[^2]: The metabolite name in bold is the name used in the conclusion.

[^3]: ChemBioDraw v.13.0.2.3021.
